On Jun 18, we issued an updated research report on Henry Schein, Inc. HSIC. The company is well positioned to gain from its extensive global foothold and diverse channel mix. However, escalating costs and expenses are putting pressure on the bottom line. Henry Schein carries a Zacks Rank #3 (Hold).
Over the past six months, Henry Schein has underperformed its industry. The stock has lost 16.6% compared with the industry's 1.9% decline.
The coronavirus pandemic has severely dented the company’s dental revenues since March. A dismal performance by the company's biggest operating segment, Dental (down 4.6%) on suspension of non-emergency procedures in response to the pandemic, is concerning. We are also disappointed with the contraction in both margins. Its decision to refrain from providing a guidance is concerning as well.
Henry Schein, Inc. Price
Henry Schein, Inc. price | Henry Schein, Inc. Quote
Governments and insurance companies continue to look for ways to contain the rising cost of healthcare, which is affecting Henry Schein’s financial operations. A weak solvency and capital structure is also deterring. Other factors like impact of group purchasing organizations and a stiff competitive landscape are bothersome.
On a positive note, Henry Schein exited the first quarter of 2020 with better-than-expected results despite the pandemic-led worldwide economic crisis. The company registered strong momentum in dental consumable merchandise and equipment internal sales in North America as well as internationally till early March, before being adversely impacted by the suspension of non-emergency procedures in response to the coronavirus outbreak.
Henry Schein also seems to be upbeat about its dental technology business, Henry Schein One. Despite business disruptions in the first quarter due to the coronavirus outbreak, the Henry Schein One dental software business holds potential to rebound.
Other products within the Henry Schein One portfolio like the beta version of its Tech Dentrix and Dentrix G7.3 are likely to maintain momentum.
Some better-ranked stocks from the broader medical space are Quest Diagnostics Incorporated DGX, Hologic, Inc. HOLX and QIAGEN N.V. QGEN.
Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic’s long-term earnings growth rate is estimated at 7%. The company presently has a Zacks Rank #2.
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
5 Stocks to Soar Past the Pandemic:In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
See the 5 high-tech stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research